The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by MARAZZITI, D.
* Articles by PALLANTI, S.
* Search for Related Content
PubMed
* Articles by MARAZZITI, D.
* Articles by PALLANTI, S.
Related Collections
* Obsessive-Compulsive Disorder
* Other Neuroleptics
Am J Psychiatry 156:1834-1835, November 1999
© 1999 American Psychiatric Association


Letter to the Editor

Effectiveness of Olanzapine Treatment for Severe Obsessive-Compulsive Disorder

DONATELIA MARAZZITI, M.D.
Pisa, Italy, and STEFANO PALLANTI, M.D.
Firenze, Italy

To the Editor: Although haloperidol and pimozide are commonly employed in treatment augmentation strategies for severe obsessive-compulsive disorder (OCD), the role of atypical neuroleptics is still unclear (1). Some reports suggest that risperidone and clozapine may induce OCD symptoms (2, 3); a patient with schizophrenia was written about recently whose obsessive-compulsive symptoms worsened with olanzapine treatment. However, we report on two severe cases of patients with OCD who dramatically improved after olanzapine was added to treatment with selective serotonin reuptake inhibitors for 3 months.

Mr. A, a 21-year-old man, had been suffering from OCD for 4 years, and his mother suffered from type II bipolar disorder. His main obsession was contamination, and his compulsions (washing rituals) occupied 8 hours a day, rendering him unfit for college or employment. Various treatments and augmentation strategies at appropriate doses had been ineffective. His Yale-Brown Obsessive Compulsive Scale total score at his first psychiatric interview was 40. He was taking sertraline, haloperidol, risperidone, and diazepam, but all psychiatric drugs were discontinued except sertraline (150 mg/day), and olanzapine (5 mg/day) titrated up to 10 mg/day over a week. After 15 days, Mr. A reported significantly lessened anxiety and, after 1 month, significantly lessened obsessive-compulsive symptoms. By the third month, his symptoms were occurring for only minutes each week (Yale-Brown Obsessive Compulsive Scale total score of 6). At this point, he decided to work and to attend evening school.

Ms. B, a 29-year-old woman, suffered from OCD (with postpartum onset 4 years previously) and had a father who suffered from OCD and alcohol abuse and a mother with type II bipolar disorder. She had order and symmetry obsessions and compulsions that consisted of repeated checking, counting rituals, and washing objects in her room, where she spent 7 hours a day. She became anxious when anyone entered her room and interfered with her rituals. Ms. B was unable to work; her familial and social relationships were severely impaired. Of the various treatments, only fluvoxamine (300 mg/day) led to temporary improvement. Ms. B was given an added 5 mg/day of olanzapine, titrated up to 15 mg over 2 weeks. After 20 days, the dysphoria and irritability that were associated with her compulsions had lessened notably, and over 3 months, her Yale-Brown Obsessive Compulsive Scale total score had decreased progressively from 40 to 8. Her compulsions then occupied only 10 minutes a day. She was undergoing cognitive behavioral therapy and intended to work.

These case reports suggest that olanzapine may help severe, otherwise untreatable patients with OCD and might help resolve frequent diagnostic dilemmas regarding patients with schizophrenia with obsessive-compulsive symptoms and patients with psychotic features with OCD. It is interesting that both patients’ mothers were suffering from type II bipolar disorder: this observation, supported by similar findings in other patients, suggests that having a family history of bipolar disorder might predict a good response to olanza­pine. Further assessment of the potential benefits of olanza­pine treatment in a defined subgroup of treatment-resistant patients with OCD is warranted.

REFERENCES

  1. Baker RW, Bermazonn PC, Wirshing DA, Chengappa KNR: Obsessions, compulsions, clozapine and risperidone. Central Nervous System Spectrums 1997; 2:6–36
  2. Patel B, Tandon R: Development of obsessive-compulsive symptoms during clozapine treatment (letter). Am J Psychiatry 1993; 150:836
  3. Morrison D, Clark D, Goldfarb E, McCoy L: Worsening of obsessive-compulsive symptoms following treatment with olanzapine (letter). Am J Psychiatry 1998; 155:855[Free Full Text]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by MARAZZITI, D.
* Articles by PALLANTI, S.
* Search for Related Content
PubMed
* Articles by MARAZZITI, D.
* Articles by PALLANTI, S.
Related Collections
* Obsessive-Compulsive Disorder
* Other Neuroleptics


Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org